Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.


SuppreMol obtains license for RA antibody from the University Hospital Regensburg

Success Stories

24 July, 2012 – The Bayerische Patentallianz GmbH, the central patent and marketing agency of 28 Bavarian universities and universities of applied sciences, licences an antibody directed against interleukin 3 (IL-3), which has been generated at the University Hospital Regensburg, to SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases. The technology could be a promising novel treatment option for Rheumatoid Arthritis.